Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin‐like growth factor binding protein‐3 levels
Open Access
- 4 July 2007
- journal article
- Published by Wiley in BJU International
- Vol. 100 (2) , 438-444
Abstract
OBJECTIVES: To investigate if the feeding of silibinin (an anticancer flavonoid) to mice inhibits in vivo renal cell carcinoma (RCC) growth via changes in insulin‐like growth factor binding protein‐3 (IGFBP‐3) levels. MATERIALS AND METHODS: Male severe combined immunodeficiency disease (SCID) mice (7 weeks old), with left kidneys injected with 1 million SN12K1 cells, were fed a silibinin‐containing diet (0.1%, 0.2% and 0.4% w/w) or control AIN‐93G diet for 39 days from 1 day after tumour engraftment. RESULTS: There was a reduction in tumour deposits and tumour kidney weight in SCID mice fed with a 0.4% silibinin‐containing diet compared to those fed the control diet. Mice with tumour injection (silibinin or control‐diet group) had constant total body weight and food consumption. The mean plasma and tumourous kidney silibinin concentrations, as measured by high‐pressure liquid chromatography‐tandem mass spectrometry, increased with escalating doses of silibinin. Using real‐time polymerase chain reaction and enzyme‐linked immunosorbent assay, the mean tissue IGFBP‐3 mRNA (in SN12K1‐implanted kidney) and plasma IGFBP‐3 levels increased in mice fed with 0.1% silibinin (tumour IGFBP‐3 mRNA levels, 156% higher vs control‐diet group, P = 0.007; and plasma IGFBP‐3 levels, 61% higher vs control‐diet group, P = 0.002) but not in mice fed with the higher silibinin pellet strengths. CONCLUSION: Oral administration of silibinin suppressed local and metastatic tumour growth in vivo in an orthotopic xenograft model of RCC. This anti‐neoplastic action of silibinin might involve IGFBP‐3. The exact mechanism through which IGFBP‐3 promotes silibinin’s anticancer effects warrants further investigation.Keywords
This publication has 26 references indexed in Scilit:
- The roles of IGF-I and IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell proliferationKidney International, 2004
- Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cellsOncogene, 2003
- INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 MEDIATES 1??,25-DIHYDROXYVITAMIN D3 GROWTH INHIBITION IN THE LNCaP PROSTATE CANCER CELL LINE THROUGH P21/WAF1Journal of Urology, 2001
- Modulation of Mitogen-Activated Protein Kinase Activation and Cell Cycle Regulators by the Potent Skin Cancer Preventive Agent SilymarinBiochemical and Biophysical Research Communications, 1999
- Skin Cancer Chemopreventive Effects of a Flavonoid Antioxidant Silymarin Are Mediated via Impairment of Receptor Tyrosine Kinase Signaling and Perturbation in Cell Cycle ProgressionBiochemical and Biophysical Research Communications, 1998
- Insulin-like Growth Factor Binding Protein-3 Induces Apoptosis in MCF7 Breast Cancer CellsBiochemical and Biophysical Research Communications, 1997
- Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) Inhibits Estrogen-Stimulated Breast Cancer Cell ProliferationBiochemical and Biophysical Research Communications, 1994
- Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanismEndocrinology, 1992
- Characterization of the invasive and metastatic phenotype in human renal cell carcinomaClinical & Experimental Metastasis, 1991
- Chemotherapy of Amanita phalloides Poisoning with Intravenous SilibininHuman Toxicology, 1983